Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 44 for your search:
Drug:
thiotepa
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
2.
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 59
Sponsor:
Other
Protocol IDs:
N06IAA
, NCT00448266
3.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
4.
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
0 to 30
Sponsor:
Other
Protocol IDs:
EUDRACT 2005-002618-40
, BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723
5.
Phase III Randomized Study of Induction Chemotherapy Comprising Vincristine, Etoposide, Cyclophosphamide, and Cisplatin With or Without High-Dose Methotrexate and Leucovorin Calcium Followed by Consolidation Chemotherapy Comprising Carboplatin and Thiotepa and Peripheral Blood Stem Cell Rescue in Pediatric Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 3
Sponsor:
NCI
Protocol IDs:
COG-ACNS0334
, ACNS0334, NCT00336024
6.
Phase III Randomized Study of Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus and Methotrexate With or Without Sirolimus in Pediatric Patients With Intermediate-Risk or High-Risk Acute Lymphoblastic Leukemia in Second Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
1 to under 22 at first relapse
Sponsor:
NCI
Protocol IDs:
COG-ASCT0431
, ASCT0431, COG-PBMTC-ONCO51, NCT00382109
7.
Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 10 at diagnosis
Sponsor:
Other
Protocol IDs:
CHLA-HEAD-START-III
, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
8.
Phase III Study of Multimodality Therapy Comprising Induction Chemotherapy, High-Dose Consolidation Chemotherapy, Autologous Stem Cell Transplantation, and/or Radiotherapy in Children With Extraocular Retinoblastoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
10 and under
Sponsor:
NCI
Protocol IDs:
COG-ARET0321
, ARET0321, NCT00554788
9.
Phase III Randomized Study of Single Versus Tandem Myeloablative Consolidation Therapy Followed by Peripheral Blood Stem Cell Transplantation in Young Patients With High-Risk Neuroblastoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
30 and under
Sponsor:
NCI
Protocol IDs:
COG-ANBL0532
, ANBL0532, NCT00567567
10.
Phase III Study of Induction Therapy Comprising Vincristine, High-Dose Methotrexate, Leucovorin Calcium, Etoposide, Cisplatin, and Cyclophosphamide Followed by 3-Dimensional Conformal Radiotherapy and High-Dose Consolidation Therapy Comprising Carboplatin, Thiotepa, and Autologous Peripheral Blood Stem Cell Rescue in Pediatric Patients With Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
21 and under at the time of definitive surgery
Sponsor:
NCI
Protocol IDs:
COG-ACNS0333
, ACNS0333, NCT00653068
11.
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
E203/2004
, IRB Project Nr. 21/2004, HSZ-001, NCT00202917
12.
Phase I/II Study of Cytoreduction Therapy Comprising Clofarabine, Melphalan, and Thiotepa Followed By Allogeneic Unmodified Hematopoietic Stem Cell Transplantion in Patients With High-Risk and/or Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 55
Sponsor:
NCI
Protocol IDs:
MSKCC-06125
, NCT00423514
13.
Prophylactic Transfer of Leukemia-Reactive T Cells After Allogeneic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
EK126092000
, NCT00460629
14.
Double Cord Blood Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-06-533
, IRB AAAC3457, NCT00801931
15.
Phase II Pilot Study of High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation and Immunotherapy With Activated T Cells in Women With Stage IV Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WSU-2007-033
, NCT00020722, RWMC-0634246
16.
Phase II Study of Tandem High-Dose Chemotherapy Comprising Melphalan, Carboplatin, Thiotepa, and Cyclophosphamide With or Without Trastuzumab (Herceptin®) Followed By Autologous Peripheral Blood Stem Cell Transplantation and Helical Tomotherapy or Loco-Regional Radiotherapy in Patients With High-Risk Stage IIIB, IIIC, or IV Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
CHNMC-05042
, IRB 05042, NCT00182793
17.
Phase II Study of a Myeloablative Preparative Regimen Comprising Busulfan, Melphalan, and Thiotepa Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Hodgkin's or Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years and younger
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-04083-L
, OHSU-IRB-248, NCT00238433
18.
High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-Cell Tumors: TAXIF II
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
P031101
, AOM04128, NCT00231582
19.
Phase II Study of a Myeloablative Regimen Comprising Busulfan, Melphalan, and Thiotepa Followed By T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Tumors of the Ewing's Family
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
40 and under
Sponsor:
Other
Protocol IDs:
MSKCC-05059
, NCT00357396
20.
Phase II Study of Mismatched, Unrelated Donor, T-Cell-Depleted Hematopoietic Stem Cell Transplantation in Patients With Myeloid Malignancies or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
60 and under
Sponsor:
NCI
Protocol IDs:
UMN-2004UC035
, UMN-MT2004-04, UMN-0405M59662, NCT00392782
21.
Phase II Study of Haploidentical Donor CD34+ Purified Peripheral Blood Stem Cell and Donor Natural Killer Cell Transplantation After a Conditioning Regimen Comprising Total-Body Irradiation, Thiotepa, Fludarabine Phosphate, and Muromonab-CD3 in Patients With Leukemia or Other Hematologic Diseases
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
45 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1965.00
, 6428, NCT00450983
22.
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
2006-0280
, NCT00429182
23.
Phase II Pilot Study of Induction Therapy Comprising Fludarabine Phosphate With Either Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplantation or Alemtuzumab in Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
60 and under
Sponsor:
Other
Protocol IDs:
GIMEMA-LLC0405
, EUDRACT-2005-00247-15, EU-20722, NCT00462332
24.
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
NYU 05-40 H12853
, PBMTC ONC-032P, NCT00528437
25.
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 55
Sponsor:
Other
Protocol IDs:
01-070
, CA23766, CA33049, NCT00587054
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
